创业慧康(300451) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥290,357,981.79, a decrease of 22.67% compared to ¥375,491,442.27 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥15,647,403.70, representing a decline of 226.60% from a profit of ¥12,359,662.56 in the previous year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥27,959,264.39, a decrease of 389.48% compared to a profit of ¥9,658,288.80 last year[4]. - The total amount of sales and management expenses decreased by 15.70% year-on-year, while net cash flow from operating activities increased by 24.16% year-on-year[14]. - Total operating revenue for the current period was CNY 290,357,981.79, a decrease of 22.7% compared to CNY 375,491,442.27 in the previous period[20]. - The net profit for the current period was a loss of CNY 14,702,055.36, compared to a profit of CNY 14,258,715.78 in the previous period[20]. - The total comprehensive income attributable to the parent company was -15,647,403.70, compared to 12,359,640.67 in the previous period[21]. - Basic and diluted earnings per share were both -0.01, compared to 0.01 in the previous period[21]. Cash Flow and Assets - The net cash flow from operating activities was -¥152,166,660.54, an improvement of 24.16% from -¥200,644,939.83 in the previous year[4]. - The company's total assets decreased to CNY 5,564,740,193.08 from CNY 5,668,132,706.72, a decline of 1.8%[19]. - Current assets totaled CNY 3,007,557,226.42, down from CNY 3,075,922,035.12, indicating a decrease of 2.2%[19]. - The total liabilities decreased to CNY 1,102,949,579.87 from CNY 1,194,672,281.56, a reduction of 7.7%[19]. - The company's cash and cash equivalents decreased to CNY 718,220,351.12 from CNY 1,018,894,565.64, a decline of 29.5%[19]. - The cash received from the sale of goods and services was 246,234,254.96, slightly up from 246,047,168.37 in the previous period[23]. - The total cash outflow from operating activities was 425,154,234.18, down from 470,935,394.21 in the previous period[24]. - The cash and cash equivalents at the end of the period were 716,252,709.50, down from 802,849,099.37 at the end of the previous period[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 82,383[11]. - The largest shareholder, Ge Hang, holds 13.24% of shares, totaling 205,074,982 shares, with 40,000,151 shares frozen[11]. - The total number of restricted shares at the end of the reporting period is 22,430,922, with no shares released during the current period[13]. Investments and Development - The company reported a significant increase of 1135.01% in trading financial assets due to increased purchases of financial products[7]. - Development expenditures grew by 595.40% due to increased investment in new product development[7]. - Financial expenses increased by 90.31% compared to the previous year, primarily due to the expiration of large time deposits[7]. - Research and development expenses increased to CNY 79,270,029.19 from CNY 68,350,032.14, an increase of 16.5%[20]. Government Support and Market Position - The company received government subsidies amounting to ¥9,112,157.03 during the reporting period[5]. - The company is positioned to benefit from policy incentives and market expansion opportunities in the healthcare information technology sector, particularly in county-level medical community information system construction[14]. Product Development and Recognition - The company signed 8 new orders worth over 10 million during the reporting period, indicating stable demand in the healthcare information technology sector[14]. - The company has integrated its DeepSeek model with medical scenarios and launched the BsoftGPT·DeepSeek medical industry all-in-one machine, covering numerous medical applications[15]. - The "Smart Diagnosis Generation Algorithm" (BsoftGPT) was recognized in the 2024 Zhejiang Province "Smart Products" list, marking a significant technological achievement[15]. - The company aims to optimize medical resource allocation through deep integration of big data analysis and machine learning, enhancing diagnostic support for doctors and improving patient care pathways[15].